NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES
Division of the National Health Laboratory Service

Monthly Respiratory Pathogens Surveillance Report (Week 48 of 2021)

Highlights

- The 2021 influenza season has not yet started although sustained detections of influenza continue in all surveillance programmes.
- 17 new cases of influenza from Western Cape (n=7), North West (n=2), Mpumalanga (n=4) and Kwa-Zulu Natal (n=4) surveillance sites were detected in week 48. To date, 386 influenza cases have been detected from Gauteng, Western Cape, North West, Eastern Cape, Mpumalanga and KwaZulu-Natal sentinel surveillance sites. From 1 January 2021 to date, influenza A(H1N1)pdm09 was the most commonly detected subtype in both influenza-like illness (ILI) surveillance (n=56/149, 38%) and pneumonia surveillance (n=63/186, 34%).
- RSV activity remains below seasonal threshold in both ILI and pneumonia surveillance programmes. From 1 January 2021 to date, RSV subgroup A was the most commonly detected subgroup in both ILI surveillance (n=42/74, 57%) and pneumonia surveillance (n=216/412, 52%).
- From 2 March 2020 to date, a total of 3 026 COVID-19 cases were detected from all surveillance programmes. An increase in number of cases in both pneumonia surveillance (from week 46) and ILI (from week 47) was noted. Of the 2 064 hospitalised COVID-19 cases reported with available data on outcome, 356 (17%) died.
- From 1 January 2021 to date, of the 1234/1749 (71%) SARS-CoV-2 positive cases with variant type results, Delta (442/1285, 34%) and Beta (205/464, 44%), were the most detected variants in pneumonia surveillance and in ILI, respectively. Delta variant predominated in both programmes (from week 22, week starting 31st May 2021 until week46). Beta variant predominated from week 47 of 2020 to week 21 of 2021.

Programme Descriptions

Programme	Influenza-like illness (ILI)	Viral Watch	National syndromic surveillance for pneumonia
Start year	2012	1984	2009
Provinces*	KZ NW WC** MP***	EC FS GP LP MP NC NW WC	GP KZ MP NW WC
Type of site	Primary health care clinics	General practitioners	Public hospitals
Case definition	**ILI**: An acute respiratory illness with a temperature (≥38°C) and cough, & onset ≤10 days **Suspected pertussis** Any person with an acute cough illness lasting ≥14 days (or cough illness of any duration for children <1 year), without a more likely diagnosis AND one or more of the following signs or symptoms: • paroxysms of coughing, • or inspiratory "whoop", • or post-tussive vomiting • or apnoea in children <1 year; OR Any person in whom a clinician suspects pertussis **Suspected SARS-CoV-2** Any person presenting with an acute (≤14 days) respiratory tract infection or other clinical illness compatible with COVID-19[β]	**ILI**: An acute respiratory illness with a temperature (≥38°C) and cough, & onset ≤10 days **Suspected SARS-CoV-2** Any person presenting with an acute (≤14 days) respiratory tract infection or other clinical illness compatible with COVID-19[β]	**SRI**: Acute (symptom onset≤10 days) or chronic (symptom onset >10) lower respiratory tract infection **Suspected pertussis** Any person with an acute cough illness lasting ≥14 days (or cough illness of any duration for children <1 year), without a more likely diagnosis AND one or more of the following signs or symptoms: • paroxysms of coughing, • or inspiratory "whoop", • or post-tussive vomiting • or apnoea in children <1 year; OR Any person in whom a clinician suspects pertussis. **Suspected SARS-CoV-2** Any person admitted with a physician-diagnosis of suspected COVID-19 and not meeting SRI case definition.
Specimens collected	Oropharyngeal & nasopharyngeal swabs	Throat and/or nasal swabs or Nasopharyngeal swabs	Oropharyngeal & nasopharyngeal swabs
Main pathogens tested**	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2	INF RSV BP SARS-CoV-2
Testing Methods	**INF and RSV** - Fast-Track Diagnostics multiplex real-time reverse transcription polymerase chain reaction (until 31 March 2021) ***B. pertussis*** Multiplex real-time PCR (Tatti *et al.*, *J Clin Microbiol* 2011) and culture (if PCR cycle threshold ≤25) **SARS-CoV-2** 1 April 2020 – 31 March 2021: Roche E gene real-time PCR essay (Corman *et al.*, *Euro Surv* 2020) 1 April 2021 to date: Allplex™ SARS-CoV-2/FluA/FluB/RSV PCR kit - positivity assigned if PCR cycle threshold is <40 for ≥1 gene targets (N, S, OR RdRp)	**INF and RSV** - Fast-Track Diagnostics multiplex real-time reverse transcription polymerase chain reaction (until 31 March 2021) ***B. pertussis*** Multiplex real-time PCR (Tatti *et al.*, *J Clin Microbiol* 2011) and culture (if PCR cycle threshold ≤25) **SARS-CoV-2** 1 April 2020 – 31 March 2021: Roche E gene real-time PCR essay Corman *et al.*, *Euro Surv* 2020) 1 April 2021 to date: Allplex™ SARS-CoV-2/FluA/FluB/RSV PCR kit - positivity assigned if PCR cycle threshold is <40 for ≥1 gene targets (N, S, OR RdRp)	**INF and RSV** - Fast Track Diagnostics multiplex real-time reverse transcription polymerase chain reaction (until 31 March 2021) ***B. pertussis*** Multiplex real-time PCR (Tatti *et al.*, *J Clin Microbiol* 2011) and culture (if PCR cycle threshold ≤25) **SARS-CoV-2** 1 April 2020 – 31 March 2021: Roche E gene real-time PCR essay (Corman *et al.*, *Euro Surv* 2020) 1 April 2021 to date: Allplex™ SARS-CoV-2/FluA/FluB/RSV PCR kit - positivity assigned if PCR cycle threshold is <40 for ≥1 gene targets (N, S, OR RdRp)

Epidemic Threshold

Thresholds are calculated using the Moving Epidemic Method (MEM), a sequential analysis using the R Language, available from: http://CRAN.R-project.org/web/package=mem) designed to calculate the duration, start and end of the annual influenza epidemic. MEM uses the 40th, 90th and 97.5th percentiles established from available years of historical data to calculate thresholds of activity. Thresholds of activity for influenza and RSV are defined as follows: Below seasonal threshold, Low activity, Moderate activity, High activity, Very high activity. For influenza, thresholds from outpatient influenza like illness (Viral Watch Programme) are used as an indicator of disease transmission in the community and thresholds from pneumonia surveillance are used as an indicator of impact of disease.

* EC: Eastern Cape; FS: Free State; GP: Gauteng; KZ: KwaZulu-Natal; LP: Limpopo; MP: Mpumalanga: NC: Northern Cape; NW: North West; WC: Western Cape
**Started in 2019
***Started in November 2020
****INF: influenza virus; RSV: respiratory syncytial virus; BP: *Bordetella pertussis*; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
[β]Symptoms include ANY of the following respiratory symptoms: cough, sore throat, shortness of breath, anosmia (loss of sense of smell) or dysgeusia (alteration of the sense of taste), with or without other symptoms (which may include fever, weakness, myalgia, or diarrhoea). Testing for SARS-CoV-2 was initiated in all three surveillance programmes in week 10 of 2020 (week starting 2 March 2020).

Data are provisional as reported to date (Data for this report drawn on (08/12/2021). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection.

Influenza

The 2021 influenza season has not yet started although sustained detections of influenza continue in all surveillance programmes. Since the first influenza positive case of 2021 was detected in pneumonia surveillance in week 9 of 2021 (week ending on the 07 March 2021), sporadic cases have been reported from week 16 to date. Of the 386 influenza cases detected in surveillance sites in 2021, the majority (n=133, 34%) were influenza A(H1N1)pdm09. In week 48, transmission is below threshold and impact is low.

ILI programme: In 2021 to date, specimens from 1 827 patients meeting ILI case definition were received from 4 ILI sites. Influenza was detected in 149 (8%) patients, of which 56 (38%) were influenza A(H1N1)pdm09, 19 (13%) influenza A(H3N2), three (2%) influenza A(inconclusive), 25 (17%) influenza A(pending subtype results), 38 (26%) influenza B(Victoria), four (3%) influenza B(lineage inconclusive) and four (3%) influenza B(lineage pending). (Fig1, Table1).

Viral Watch programme: In 2021 to date, specimens were received from 227 patients from Viral Watch sites in 6 of the 8 provinces participating in surveillance. Influenza was detected in 29 (13%) patients, of which 10 (35%) were influenza A(H1N1)pdm09, five (17%) influenza A(H3N2), three (10%) influenza A(pending results), eight (28%) influenza B(Victoria) and three (10%) influenza B(lineage inconclusive). (Fig7, Table6)

Pneumonia surveillance: Since the beginning of 2021, specimens from 5 810 patients with severe respiratory illness (SRI) were received from the 6 sentinel sites. Influenza was detected in 186 (3%) patients, of which 63 (34%) were influenza A(H1N1)pdm09, 29 (16%) influenza A(H3N2), five (3%) influenza A(subtype inconclusive), 32 (17%) influenza A(pending subtype results), 49 (26%) influenza B(Victoria), seven (4%) were influenza B(lineage inconclusive) and one (1%) influenza B(lineage pending results). (Fig11, Table10)

In addition, influenza was detected in 22 (3%) of 844 specimens, of which four (18%) were influenza A(H1N1)pdm09, 17 (77%) influenza B(Victoria) and one (5%) was influenza B(inconclusive) from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia/ILI surveillance case definition.

Respiratory syncytial virus

In 2021 to date, RSV detection has been reported from all surveillance programmes, activity remains below seasonal threshold. Of the 513 RSV cases detected in 2021, the majority (n=268, 52%) were RSV subgroup A

ILI programme: In 2021 to date, 1 827 specimens from patients meeting the ILI case definition were tested and RSV was detected in 74 (5%) patients. Of which, 42 (57%) were RSV subgroup A, 31 (42%) RSV subgroup B and one (1%) was RSV (subgroup inconclusive). (Fig3, Table2)
Viral Watch programme: In 2021 to date, 227 specimens from viral watch patients were tested and RSV was detected in specimens of six (3%) patients. Of which, three (50%) were RSV subgroup A, two (33%) RSV subgroup B and one (17%) was RSV (subgroup inconclusive). (Fig8, Table7)
Pneumonia surveillance: Since the beginning of 2021, 5 810 specimens were tested and RSV was detected in specimens of 412 (7%) patients. Of which, 216 (53%) were RSV subgroup A, 190 (47%) RSV subgroup B, five (1%) RSV (subgroup inconclusive) and one (<1%) RSV (pending subgroup). (Fig13, Table11)

In addition, RSV was detected in 21 of 844 (3%) specimens, of which seven (33%) were RSV subgroup A, 13 (62%) RSV subgroup B and one (5%) was RSV (subgroup inconclusive) from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia/ILI surveillance case definition.

Bordetella pertussis

ILI programme: From 1 January 2021 to date, combined nasopharyngeal and oropharyngeal specimens were tested from 1 810 patients and *B. pertussis* was not detected. (Fig4, Table3)

Pneumonia surveillance: During the same period, combined nasopharyngeal and oropharyngeal specimens were tested from 5 800 patients and *B. pertussis* was detected in one (0.02%). (Fig14, Table12). The case was a two month old female, identified in week 33 from Rahima Moosa Hospital, Gauteng Province.

In addition, *B. pertussis* was not detected in 845 specimens from patients who met suspected *B. pertussis* case definition but did not meet the pneumonia/ILI surveillance case definition.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)

ILI programme: From March 2020 to date, 3 141 patients were tested and SARS-CoV-2 was detected in 585 (19%) patients. From 1 January 2021 to date, of the 343/464 (74%) with data on variant type, majority (205/464, 44%) were Beta variant which predominated from week1 to week 24, followed by Delta (145/464, 31%) variant which predominated from week 25 to week 40. (Fig5, Table4)
Viral Watch programme: From March 2020 to date, 506 patients presenting with ILI were tested and SARS-CoV-2 was detected in 90 (18%) patients. From 1 January 2021, of the 21/90 (23%) with data on variant type, majority were (19/21, 90%) were Delta variant which dominated from week 25 to week 30. (Fig10, Table9)
Pneumonia surveillance: From March 2020 to date, 9 825 patients with severe respiratory illness (SRI) were tested and SARS-CoV-2 was detected in 2 095 (21%) patients. From 1 January 2021 to date, of the 891/1285 (69%) with data on variant type, majority were (442/1285, 34%) were Delta variant which dominated from week 22 to week 46 followed by Beta (403/1285, 31%) variant which dominated from week 1 to 25. (Fig16, Table14)

In addition, SARS-CoV-2 was detected in 212 of 1047 (20%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet the pneumonia/ILI surveillance case definitions.



Figure 1. Number of influenza positive cases* by influenza subtype and lineage and detection rate*** by week, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021**

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces
**Influenza was detected in 16 (3%) of 637 specimens, of which 2 (13%) were influenza A(H1N1)pdm09, 13 (81%) influenza B(Victoria) and one (6%) was influenza B(inconclusive) from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.
***Only reported for weeks with >10 specimens submitted
Inconclusive: insufficient viral load in sample and unable to characterise further

Data are provisional as reported to date (Data for this report drawn on (08/12/2021). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection.

Table 1. Number of laboratory confirmed influenza cases by subtype and lineage and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021**

Clinic (Province)	A(H1N1)pdm 09	A(H3N2)	A subtype inconclusive	A subtype pending results[β]	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results[β]	Total samples
Agincourt (MP)	1	2	1	1	0	0	0	0	245
Eastridge (WC)	2	6	0	6	6	0	0	1	243
Edendale Gateway (KZ)	5	1	0	3	15	0	3	1	259
Jouberton (NW)	43	5	1	3	13	0	0	0	789
Mitchell's Plain (WC)	5	5	1	12	4	0	1	2	291
Total:	56	19	3	25	38	0	4	4	1 827

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga
Inconclusive: insufficient viral load in sample and unable to characterise further

**Influenza was detected in 16 (3%) of 637 specimens, of which 2 (13%) were influenza A(H1N1)pdm09, 13 (81%) influenza B(Victoria) and one (6%) was influenza B(inconclusive) from patients who met suspected SARS-CoV-2 case definition but did not meet Influenza-like illness (ILI) case definition. These are not included in the table.
[β]influenza A subtype or B lineage results are pending



Figure 2. Number of patients testing positive for respiratory syncytial virus* by province and detection rate by week, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021**

**RSV was detected from 15 of 637 (2%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Data are provisional as reported to date (Data for this report drawn on (08/12/2021). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection.



Figure 3. Number of patients testing positive for respiratory syncytial virus by subgroup and detection rate by week, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021**

Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified

**RSV was detected from 15 of 637 (2%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 2. Number of patients testing positive for respiratory syncytial virus (RSV) by subgroups identified and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021**

Clinic (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Agincourt (MP)	12	7	0	0	0	245
Eastridge (WC)	24	1	0	0	0	243
Edendale Gateway (KZ)	1	6	0	0	0	259
Jouberton (NW)	2	17	0	1	0	789
Mitchell's Plain (WC)	3	0	0	0	0	291
Total	42	31	0	1	0	1 827

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga
Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified
*RSV results for subgroups are pending

**RSV was detected from 15 of 637 (2%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.



Figure 4. Number of patients testing positive for *B. pertussis* and detection rate by month, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021

**No *B. pertussis* was detected in 628 specimens of patients who met the suspected *B. pertussis* case definition but did not meet Influenza-like illness case definition. These are not included in the epidemiological curve

Table 3. Number of patients testing positive for *B. pertussis* identified and total number of samples tested by province, Influenza-like illness (ILI) surveillance primary health care clinics, 04/01/2021 – 05/12/2021**

Clinic (Province)	*B. pertussis* Positive**	Total samples
Agincourt (MP)	0	242
Eastridge (WC)	0	243
Edendale Gateway (KZ)	0	259
Jouberton (NW)	0	779
Mitchell's Plain (WC)	0	287
Total:	0	1 810

KZ: KwaZulu-Natal; NW: North West; WC: Western Cape; MP: Mpumalanga

**No *B. pertussis* was detected in 628 specimens of patients who met the suspected *B. pertussis* case definition but did not meet Influenza-like illness case definition. These are not included in the table.



Figure 5. Number of patients testing positive for SARS-CoV-2* by province and detection rate by week, Influenza-like illness (ILI) surveillance primary health care clinics, 02/03/2020 – 05/12/2021

*Specimens from patients with influenza-like illnesses at 5 sentinel sites in 4 provinces

**SARS-CoV-2 was detected in 150 of 769 (20%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the epidemiological curve.

Table 4. Number of patients positive for SARS-CoV-2 identified and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance primary health care clinics, 02/03/2020 – 05/12/2021

Clinic (Province)	SARS-CoV-2 positive	Total samples tested
Agincourt (MP)	62	275
Eastridge (WC)	60	732
Edendale Gateway (KZ)	73	402
Jouberton (NW)	298	1112
Mitchell's Plain (WC)	92	620
Total:	585	3 141

KZ: KwaZulu-Natal; NW: North West; WCP: Western Cape; MP: Mpumalanga (started enrolling on the 10th November 2020)

**SARS-CoV-2 was detected in 150 of 769 (20%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet influenza-like illness (ILI) case definition. These are not included in the table.



Figure 6. Number and detection rate of laboratory confirmed SARS-CoV-2* cases by variant type (variant PCR/sequencing) and week, Influenza-like illness (ILI) surveillance primary health care clinics, 02/03/2020 – 05/12/2021

*Specimens are from patients with influenza-like illness at 5 sentinel sites in 4 provinces who met suspected SARS-CoV-2 case definition and met pneumonia (SRI) case definition as well as those that did not meet the ILI case definition.

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding results

Table 5. Number of SARS-CoV-2* positive cases by variant (variant PCR and/or sequencing) identified and total number of samples tested by clinic and province, Influenza-like illness (ILI) surveillance primary health care clinics, 02/03/2020 – 05/12/2021

Clinic (Province)	Non-Alpha/Beta/Delta	20I (Alpha)	20H (Beta)	21A (Delta)	20D (C.1.2)	Pending	Unable to assign	Total SARS-CoV-2 positive*
Agincourt (MP)	4	0	29	19	0	28	2	82
Eastridge (WC)	20	0	19	7	0	5	2	60
Edendale Gateway (KZ)	27	0	24	32	1	22	5	111
Jouberton (NW)	61	15	105	74	7	58	24	344
Mitchell's Plain (WC)	35	0	28	13	0	6	5	87
Total:	147	15	205	145	8	119	38	677

KZ: KwaZulu-Natal; NW: North West; WCP: Western Cape; MP: Mpumalanga (started enrolling on the 10th November 2020)
*Specimens are from patients with influenza-like illness at 5 sentinel sites in 4 provinces who met suspected SARS-CoV-2 case definition and met pneumonia (SRI) case definition as well as those that did not meet the ILI case definition.

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding results



Figure 7. Number of positive patients* by influenza subtype and lineage and detection rate by week, ILI surveillance - Viral Watch, 04/01/2021 – 05/12/2021**

*Specimens from patients with Influenza-like illnesses at 90 sentinel sites in 8 provinces
** Only reported for weeks with >10 specimens submitted.
Inconclusive: insufficient viral load in sample and unable to characterise further

Table 6. Number of laboratory confirmed influenza cases by influenza subtype and lineage and total number of samples tested by province, ILI surveillance - Viral Watch, 04/01/2021 – 05/12/2021

Province	A(H1N1) pdm09	A(H3N2)	A subtype inconclusive	A subtype pending results	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results*	Total samples
Eastern Cape	0	0	0	0	2	0	0	0	4
Free State	1	0	0	0	0	0	0	0	4
Gauteng	6	2	0	0	5	0	3	0	170
Limpopo	0	0	0	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	0	0	0	3
North West	0	0	0	0	0	0	0	0	2
Northern Cape	0	0	0	0	0	0	0	0	0
Western Cape	3	3	0	3	1	0	0	0	44
Total:	10	5	0	3	8	0	3	0	227

*Inconclusive: insufficient viral load in sample and unable to characterise further

From 04 January 2021 to date, no patients were tested for influenza at the time of entry into South Africa following travel abroad.

Patients known to have acquired influenza abroad are not included in the table or epidemiological curve.



Figure 8. Number of RSV positive cases testing positive for respiratory syncytial virus (RSV)* by subgroup and detection rate by week, ILI surveillance - Viral Watch, 04/01/2021 – 05/12/2021

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces
*RSV results for subgroups are pending

Table 7. Number of RSV positive cases identified and total number of samples tested by province, ILI surveillance - Viral Watch, 04/01/2021 – 05/12/2021

Province	RSV A	RSV B	RSV AB	RSV subgroup inconclusive	RSV subgroup pending results*	Total samples tested
Eastern Cape	0	0	0	0	0	4
Free State	0	0	0	0	0	4
Gauteng	2	2	0	0	0	170
Limpopo	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	3
North West	0	0	0	0	0	2
Northern Cape	0	0	0	0	0	0
Western Cape	1	0	0	1	0	44
Total:	3	2	0	1	0	227

*RSV results for subgroups are pending



Figure 9. Number of patients testing positive for SARS-CoV-2*, by site and detection rate by week, ILI surveillance - Viral Watch, 02/03/2020 – 05/12/2021

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Table 8. Number of SARS-CoV-2 positive cases identified and total number tested by province, ILI surveillance - Viral Watch, 02/03/2020 – 05/12/2021

Province	SARS-CoV-2 positive	Total samples tested
Eastern Cape	1	8
Free State	1	18
Gauteng	70	330
Limpopo	0	2
Mpumalanga	1	8
North West	0	2
Northern Cape	0	2
Western Cape	17	136
Total:	90	506

Data are provisional as reported to date (Data for this report drawn on (08/12/2021). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection.



Figure 10. Number and detection rate of laboratory confirmed SARS-CoV-2* cases by variant type (variant PCR/sequencing) and week, ILI surveillance - Viral Watch, 02/03/2020 – 05/12/2021

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results

Table 9. Number of SARS-CoV-2* positive cases by variant (variant PCR and/or sequencing) identified and total number of samples tested by province, ILI surveillance - Viral Watch, 02/03/2020 – 05/12/2021

Clinic (Province)	Non-Alpha/Beta/Delta	20I (Alpha)	20H (Beta)	21A (Delta)	20D (C.1.2)	Pending	Unable to assign	Total SARS-CoV-2 positive
Eastern Cape	0	0	0	0	0	1	0	1
Free State	0	0	0	0	0	1	0	1
Gauteng	2	0	0	18	0	50	0	70
Limpopo	0	0	0	0	0	0	0	0
Mpumalanga	0	0	0	0	0	1	0	1
North West	0	0	0	0	0	0	0	0
Northern Cape	0	0	0	0	0	0	0	0
Western Cape	0	0	0	1	0	16	0	17
Total:	2	0	0	19	0	69	0	90

*Specimens from patients with Influenza-like illnesses at 92 sentinel sites in 8 provinces

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results



Figure 11. Number of positive influenza positive cases* by influenza subtype and lineage and detection rate*** by week, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021**

*Specimens from patients hospitalized with pneumonia at 7 sentinel sites in 5 provinces
**Influenza was detected in five (2%) of 207 specimens, of which one (20%) was influenza A(H1N1)pdm09 and four (80%) were influenza B(Victoria) from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition.These are not included in the epidemiological curve.
***Only reported for weeks with >10 specimens submitted
Inconclusive: insufficient viral load in sample and unable to characterise further

Table 10. Number of laboratory confirmed influenza cases by subtype and lineage and total number of samples tested by hospital, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021**

Hospital (Province)	A(H1N1)pdm09	A(H3N2)	A subtype inconclusive	A subtype pending results***	B/Victoria	B/Yamagata	B lineage inconclusive	B lineage pending results***	Total samples
Edendale (KZ)	2	2	0	4	12	0	0	0	908
Helen Joseph-Rahima Moosa (GP)	23	14	2	1	17	0	5	0	1537
Klerksdorp-Tshepong (NW)	12	1	1	8	4	0	2	0	913
Mapulaneng-Matikwana (MP)	3	1	0	2	1	0	0	0	561
Red Cross (WC)	14	7	0	8	12	0	0	0	756
Mitchell's Plain (WC)	8	3	0	6	2	0	0	1	887
Tintswalo (MP)	1	1	2	3	1	0	0	0	248
Total:	63	29	5	32	49	0	7	1	5 810

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape
Inconclusive: insufficient viral load in sample and unable to characterise further

**Influenza was detected in five (2%) of 207 specimens, of which one (20%) was influenza A(H1N1)pdm09 and four (80%) were influenza B(Victoria) from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.
***influenza A subtype or B lineage results are pending

Data are provisional as reported to date (Data for this report drawn on (08/12/2021). Number of consultations/specimens are reported/analysed by date of consultation/specimen collection.



Figure 12. Number of patients testing positive for respiratory syncytial virus* by province and detection rate by week, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021

*RSV was detected in six of 207 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.



Figure 13. Number of patients testing positive for respiratory syncytial virus* by subgroup and detection rate by week, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021

Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified
RSV subgroup pending: RSV results for subgroups are pending
*RSV was detected in six of 207 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 11. Number of patients positive for respiratory syncytial virus subgroups by subgroups identified and total number of samples tested by hospital, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021**

Hospital (Province)	RSVA	RSVB	RSVAB	RSV subgroup inconclusive	RSV subgroup pending*	Total samples
Edendale (KZ)	10	29	0	0	0	908
Helen Joseph-Rahima Moosa (GP)	37	42	0	1	0	1537
Klerksdorp-Tshepong (NW)	8	45	0	1	0	913
Mapulaneng-Matikwana (MP)	21	7	0	0	0	561
Red Cross (WC)	88	51	0	2	1	756
Mitchell's Plain (WC)	42	13	0	1	0	887
Tintswalo (MP)	10	3	0	0	0	248
Total:	216	190	0	5	1	5810

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape
Inconclusive: insufficient viral load in sample and unable to characterise further
RSV AB: Both RSV A and B subgroup identified
*RSV results for subgroups are pending

**RSV was detected in six of 207 (3%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table



Figure 14. Number of patients testing positive for *B. pertussis* and detection rate by month, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021

**No *B. pertussis* was detected in 209 specimens of patients who met the suspected *B. pertussis* case definition but did not meet Pneumonia Surveillance case definition. These are not included in the epidemiologic curve.

Table 12. Number of patients testing positive for *B. pertussis* identified and total number of samples tested by hospital and province, pneumonia surveillance public hospitals, 04/01/2021 – 05/12/2021**

Hospital (Province)	*B. pertussis* Positive**	Total samples
Edendale (KZ)	0	906
Helen Joseph-Rahima Moosa (GP)	1	1531
Klerksdorp-Tshepong (NW)	0	911
Mapulaneng-Matikwana (MP)	0	558
Red Cross (WC)	0	755
Mitchell's Plain (WC)	0	892
Tintswalo (MP)	0	247
Total:	1	5 800

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape

**No *B. pertussis* was detected in 209 specimens of patients who met the suspected *B. pertussis* case definition but did not meet Pneumonia Surveillance case definition. These are not included in the table



Figure 15. Number of patients testing positive for SARS-CoV-2*β by province and detection rate by week, pneumonia surveillance public hospitals, 02/03/2020 – 05/12/2021

*Specimens from patients hospitalized with pneumonia at 6 sentinel sites in 5 provinces

*βSARS-CoV-2 was detected in 62 of 278 (22%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the epidemiological curve.

Table 13. Number of patients positive for SARS-CoV-2 and total number of samples tested by hospital, pneumonia surveillance public hospitals, 02/03/2020 – 05/12/2021**

Hospital (Province)	SARS-CoV-2 positive	Total samples tested
Edendale (KZ)	466	1 755
Helen Joseph-Rahima Moosa (GP)	516	2 383
Klerksdorp-Tshepong (NW)	480	1 506
Mapulaneng-Matikwana (MP)	167	863
Red Cross (WC)	62	1 714
Mitchell's Plain (WC)	352	1 357
Tintswalo (MP)	52	247
Total:	2 095	9 825

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga; WC: Western Cape

**SARS-CoV-2 was detected in 62 of 278 (22%) specimens from patients who met suspected SARS-CoV-2 case definition but did not meet pneumonia (SRI) case definition. These are not included in the table.



Figure 16. Number and detection rate of laboratory confirmed SARS-CoV-2 cases* by variant type (variant PCR/sequencing), pneumonia surveillance public hospitals, 02/03/2020 – 05/12/2021

*Specimens are from hospitalized patients at 7 sentinel sites in 5 provinces who met suspected SARS-CoV-2 case definition and met pneumonia (SRI) case definition as well as those that did not meet the SRI case definition.
Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding results

Table 14. Number of SARS-CoV-2 positive cases* by variant (variant PCR and/or sequencing) identified and total number of samples tested by hospital, pneumonia surveillance public hospitals, 02/03/2020 – 05/12/2021

Hospital (Province)	Non-Alpha/Beta/ Delta	20I (Alpha)	20H (Beta)	21A (Delta)	20D (C.1.2)	Pending	Unable to assign	SARS-CoV-2 positive*
Edendale (KZ)	98	1	77	87	7	152	37	459
Helen Joseph-Rahima Moosa (GP)	124	5	122	107	16	57	56	487
Klerksdorp-Tshepong (NW)	120	9	113	96	12	64	33	447
Mapulaneng-Matikwana (MP)	15	0	91	30	1	39	18	194
Red Cross (WC)	16	0	6	7	1	13	1	44
Mitchell's Plain (WC)	51	0	50	99	0	98	42	340
Tintswalo (MP)	0	1	12	16	0	20	1	50
Total:	424	16	471	442	37	443	188	2021

GP: Gauteng; KZ: KwaZulu-Natal; NW: North West; MP: Mpumalanga (Tintswalo started enrolling on the 10th Feb 2021); WC: Western Cape
*Specimens are from hospitalized patients at 7 sentinel sites in 5 provinces who met suspected SARS-CoV-2 case definition and met pneumonia (SRI) case definition as well as those that did not meet the SRI case definition.

Unable to assign: no lineage assigned due to poor- sequence quality **OR** low viral load (ct=>35) **OR** variant PCR could not assign variant and no sequencing result
Pending: outstanding variant results

Table17: Characteristics of individuals with laboratory-confirmed SARS-CoV-2, enrolled in influenza-like illness (ILI) and pneumonia surveillance programmes, South Africa, 2 March 2020 - 05 December 2021

Characteristic	Influenza–like illness (ILI), public-sector, n=735 (%)	Pneumonia, n=2 157 (%)
Age group (years)		
0-9	53/735 (7)	141/2157 (7)
10-19	55/735 (7)	15/2157 (1)
20-39	346/735 (47)	421/2157 (19)
40-59	226/735 (31)	795/2157 (37)
60-79	53/735 (7)	708/2157 (33)
≥80	2/735 (<1)	77/2157 (4)
Sex-female	440/735 (60)	1324/2157 (61)
Province*		
Gauteng	N/A	535/2157 (25)
KwaZulu-Natal	118/735 (16)	473/2157 (22)
Mpumalanga**	88/735 (12)	254/2157 (12)
North West	373/735 (51)	480/2157 (22)
Western Cape	156/735 (21)	415/2157 (19)
Race		
Black	554/732 (76)	1713/2150 (80)
Coloured	146/732 (20)	330/2150 (15)
Asian/Indian	4/732 (1)	52/2150 (2)
White	22/732 (3)	44/2150 (2)
Other	6/732 (1)	11/2150 (<1)
Variant[$$]		
Non-Alpha/Beta/Delta	147/639 (23)	424/1833 (23)
20I(Alpha)	15/639 (2)	16/1833 (1)
20H(Beta)	205/639 (32)	471/1833 (26)
21A(Delta)	145/639 (23)	442/1833 (24)
20D(C.1.2)	8/639 (1)	37/1833 (2)
Pending results	121/639 (19)	443/1833 (24)
Presentation		
Fever	574/732 (78)	985/2150 (46)
Cough	713/732 (97)	2040/2150 (95)
Shortness of breath	267/732 (37)	1666/2150 (77)
Chest pain	320/732 (44)	865/2150 (40)
Diarrhoea	55/732 (8)	138/2150 (6)
Underlying conditions		
Hypertension[$]	17/691 (2)	249/1896 (13)
Cardiac	2/732 (<1)	49/2150 (2)
Lung disease	0/732 (0)	3/2150 (<1)
Diabetes	17/732 (2)	442/2150 (21)
Cancer	2/732 (<1)	13/2150 (1)
Tuberculosis	11/732 (2)	59/2150 (3)
HIV-infection	137/732 (19)	481/2150 (22)
Other ***	13/732 (2)	94/2150 (4)
SARS-CoV-2 Vaccine		
Pfizer-BioNTech (1st dose)	13/444 (3)	86/1257 (7)
Pfizer-BioNTech (2nd dose)	3/444 (0.7)	13/1257 (1)
Johnson & Johnson	17/444 (4)	15/1257 (1)
Unknown	0/444 (0)	5/1257 (0.4)
Management		
Oxygen therapy	9/732 (1)	1663/2150 (77)
ICU admission	N/A	50/2150 (2)
Ventilation	N/A	56/2150 (3)
Outcome****		
Died	0/718 (0)	356/2064 (17)

*ILI surveillance not conducted in Gauteng province
**Mpumalanga (ILI site started enrolling on the 10th November 2020 and an additional SARI site started enrolling on the 10th February 2021)
***Chronic lung, liver and kidney disease, organ transplant, pregnancy, malnutrition, obesity, tracheostomy, prematurity, seizure, stroke, anaemia, asplenia, burns, Systemic lupus erythematosus, seizures
****Outcome includes patients who are still hospitalised, have been discharged or referred, and those who died
[$]Data on hypertension was not collected on all cases.
[$$] These individuals with unassigned sequence are not included, ILI (n=181) and SRI (n=594)

Note: Children may be over-represented amongst hospitalised patients due to the inclusion of a large paediatric hospital in Cape Town.
Of the 356 patients who died, three were in <20 age group, 27 in the 20-39 year age group, 120 in the 40-59 year age group, and 206 were ≥60 years; 202/356 (57%) were female.

Methods

SARS-CoV-2 Testing

March 2020 – March 2021: SARS-CoV-2 was detected using the Roche E gene real-time PCR assay (Corman et al. *Euro Surveillance* 2020) with cycle threshold (C_t) <40 interpreted as positive for SARS-CoV-2. From April 2021 to date the laboratory changed to the Allplex™ SARS-CoV-2/FluA/FluB/RSV kit (Seegene Inc., Seoul, South Korea), with positivity assigned if the PCR cycle threshold (C_t) was <40 for ≥1 gene targets (N, S or RdRp).

A confirmed SARS-CoV-2 case is a person of any age enrolled in surveillance with laboratory confirmation of SARS-CoV-2 infection by PCR. Only positive SARS-CoV-2 specimens on PCR are further tested to determine variant/lineage type by variant PCR or genomic sequencing.

Variant PCR

Allplex™ SARS-CoV-2 Variants I PCR detects Alpha and Beta/Gamma variants. The assay was conducted on all SARS-CoV-2-positive samples from 1 March 2020 – 30 June 2021.

Allplex™ SARS-CoV-2 Variants II PCR detects Delta variant and distinguishes Beta from Gamma. The assay was conducted on SARS-CoV-2-positive samples from 1 Jan to 30 June 2021.

Extraction: Total nucleic acids were extracted from 200µl NP/OP samples in universal or viral transport medium using a MagNA Pure 96 automated extractor and DNA/Viral NA Small Volume v2.0 extraction kit (Roche Diagnostics, Mannheim, Germany).

SARS-CoV-2 genomic surveillance

SARS-CoV-2 Whole-Genome Sequencing and Genome Assembly

RNA Extraction

RNA was extracted either manually or automatically in batches, using the QIAamp viral RNA mini kit (QIAGEN, CA, USA) or the Chemagic 360 using the CMG-1049 kit (PerkinElmer, MA, USA). A modification was done on the manual extractions by adding 280 µl per sample, in order to increase yields. 300 µl of each sample was used for automated magnetic bead-based extraction using the Chemagic 360. RNA was eluted in 60 µl of the elution buffer. Isolated RNA was stored at -80 °C prior to use.

PCR and Library Preparation

Sequencing was performed using the Illumina COVIDSeq protocol (Illumina Inc., CA, USA) or nCoV-2019 ARTIC network sequencing protocol v3 (https://artic.network/ncov-2019). These are amplicon-based next-generation sequencing approaches. Briefly, for the nCoV-2019 ARTIC network sequencing protocol, the first strand synthesis was carried out on extracted RNA samples using random hexamer primers from the SuperScript IV reverse transcriptase synthesis kit (Life Technologies, CA, USA) or LunaScript RT SuperMix Kit (New England Biolabs (NEB), MA , USA). The synthesized cDNA was amplified using multiplex polymerase chain reactions (PCRs) using ARTIC nCoV-2019 v3 primers. For the COVIDSeq protocol, the first strand synthesis was carried out using random hexamer primers from Illumina and the synthesized cDNA underwent two separate multiplex PCR reactions.

For Illumina sequencing using the nCoV-2019 ARTIC network sequencing protocol, the pooled PCR products underwent bead-based tagmentation using the Nextera Flex DNA library preparation kit (Illumina Inc., CA, USA). The adapter-tagged amplicons were cleaned up using AmpureXP purification beads (Beckman Coulter, High Wycombe, UK) and amplified using one round of PCR. The PCRs were indexed using the Nextera CD indexes (Illumina Inc., CA, USA) according to the manufacturer's instructions. For

COVIDSeq sequencing protocol, pooled PCR amplified products were processed for tagmentation and adapter ligation using IDT for Illumina Nextera UD Indexes. Further enrichment and cleanup was performed as per protocols provided by the manufacturer (Illumina Inc., CA, USA). Pooled samples from both COVIDSeq protocol and nCoV-2019 ARTIC network protocol were quantified using Qubit 3.0 or 4.0 fluorometer (Invitrogen Inc., MA, USA) using the Qubit dsDNA High Sensitivity assay according to manufacturer's instructions. The fragment sizes were analyzed using TapeStation 4200 (Invitrogen Inc., MA, USA). The pooled libraries were further normalized to 4nM concentration and 25 µl of each normalized pool containing unique index adapter sets were combined in a new tube. The final library pool was denatured and neutralized with 0.2 N sodium hydroxide and 200 mM Tris-HCL (pH7), respectively. 1.5 pM sample library was spiked with 2% PhiX. Libraries were loaded onto a 300-cycle NextSeq 500/550 HighOutput Kit v2 and run on the Illumina NextSeq 550 instrument (Illumina Inc., CA, USA).

Assembly, Processing and Quality Control of Genomic Sequences

Raw reads from Illumina sequencing were assembled using the Exatype NGS SARS-CoV-2 pipeline v1.6.1, (https://sars-cov-2.exatype.com/). The resulting consensus sequence was further manually polished by considering and correcting indels in homopolymer regions that break the open reading frame (probably sequencing errors) using Aliview v1.27, (http://ormbunkar.se/aliview/) (Larsson, 2014). Mutations resulting in mid-gene stop codons and frameshifts were reverted to wild type. All assemblies determined to have acceptable quality (defined as having at least 1 000 000 reads and at least 40 % 10 X coverage) were deposited on GISAID (https://www.gisaid.org/) (Elbe & Buckland-Merrett, 2017; Shu & McCauley, 2017).

Classification of Lineage, Clade and Associated Mutations

Assembled genomes were assigned lineages using the 'Phylogenetic Assignment of Named Global Outbreak Lineages' (PANGOLIN) software suite (https://github.com/hCoV-2019/pangolin) (Rambaut et al., 2020), a tool used for dynamic SARS-CoV-2 lineage classification. The SARS-CoV-2 genomes in our dataset were also classified using the clade classification proposed by NextStrain (https://nextstrain.org/), a tool built for real-time tracking of the pathogen evolution (Hadfield et al., 2018).